Results 201 to 210 of about 48,920 (248)
Some of the next articles are maybe not open access.
Interventional Cardiology Clinics, 2022
In-stent restenosis (ISR) remains a potential complication after percutaneous coronary intervention, even in the era of drug-eluting stents, and its treatment remains suboptimal. Neoatherosclerosis is an important component of the pathology of ISR and is accelerated in drug-eluting stents compared with bare-metal stents.
Kenji, Kawai +2 more
openaire +2 more sources
In-stent restenosis (ISR) remains a potential complication after percutaneous coronary intervention, even in the era of drug-eluting stents, and its treatment remains suboptimal. Neoatherosclerosis is an important component of the pathology of ISR and is accelerated in drug-eluting stents compared with bare-metal stents.
Kenji, Kawai +2 more
openaire +2 more sources
Surgical Clinics of North America, 1998
The multitude of actions and interacting components involved in inciting and sustaining myointimal hyperplasia and restenosis effectively precludes the use of a single type of intervention. No pharmacologic approach has been conclusively shown to prevent coronary restenosis after balloon angioplasty or graft restenosis after peripheral arterial bypass.
S A, Kagan, S I, Myers
openaire +2 more sources
The multitude of actions and interacting components involved in inciting and sustaining myointimal hyperplasia and restenosis effectively precludes the use of a single type of intervention. No pharmacologic approach has been conclusively shown to prevent coronary restenosis after balloon angioplasty or graft restenosis after peripheral arterial bypass.
S A, Kagan, S I, Myers
openaire +2 more sources
Archives of Surgery, 1985
To the Editor.—We would like to thank Dr Thompson for his comments on our recent article.1We agree that our follow-up was short; however, a recent update of our results indicates a cumulative stroke-free survival of 97% at three years, with 65 patients having been followed up prospectively for this time period.
M P, Colgan, V, Kingston, G, Shanik
openaire +2 more sources
To the Editor.—We would like to thank Dr Thompson for his comments on our recent article.1We agree that our follow-up was short; however, a recent update of our results indicates a cumulative stroke-free survival of 97% at three years, with 65 patients having been followed up prospectively for this time period.
M P, Colgan, V, Kingston, G, Shanik
openaire +2 more sources
Progress in Cardiovascular Diseases, 1997
Recent studies have allowed a better understanding of the biology of restenosis. Neointimal thickening--also referred to as neointimal hyperplasia--occurs in response to experimental arterial injury. This process involves different steps which include smooth muscle cell activation, proliferation, and migration, and the production of extracellular ...
C, Bauters, J M, Isner
openaire +2 more sources
Recent studies have allowed a better understanding of the biology of restenosis. Neointimal thickening--also referred to as neointimal hyperplasia--occurs in response to experimental arterial injury. This process involves different steps which include smooth muscle cell activation, proliferation, and migration, and the production of extracellular ...
C, Bauters, J M, Isner
openaire +2 more sources
Interventional Cardiology Clinics, 2016
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. The mean time from percutaneous coronary intervention (PCI) to ISR was 12 months with drug-eluting stents (DES) and 6 months with bare metal stents (BMS). ISR typically presents as recurrent angina. The use of DES has significantly reduced the rate of ISR compared with BMS.
Michael S, Lee, Gaurav, Banka
openaire +2 more sources
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. The mean time from percutaneous coronary intervention (PCI) to ISR was 12 months with drug-eluting stents (DES) and 6 months with bare metal stents (BMS). ISR typically presents as recurrent angina. The use of DES has significantly reduced the rate of ISR compared with BMS.
Michael S, Lee, Gaurav, Banka
openaire +2 more sources
Journal of the American Academy of Nurse Practitioners, 1996
Return of angina within 6 months of a catheter-based treatment of coronary artery disease usually reflects restenosis due to an overly aggressive local healing response to the procedure-related arterial injury. The restenotic lesion should be treated aggressively.
C, Brown +5 more
openaire +2 more sources
Return of angina within 6 months of a catheter-based treatment of coronary artery disease usually reflects restenosis due to an overly aggressive local healing response to the procedure-related arterial injury. The restenotic lesion should be treated aggressively.
C, Brown +5 more
openaire +2 more sources
Hyperhomocysteinemia and Restenosis
European Journal of Cardiovascular Prevention & Rehabilitation, 2001This study was undertaken to assess the effect of plasma homocysteine level on angiographic restenosis 6 months after coronary angioplasty.The plasma homocysteine level was measured in 100 consecutive patients at the time of coronary angioplasty, 56 patients who attended a 6-month follow-up angiogram being enrolled to the study; the 44 patients without
S D, Kumbasar +9 more
openaire +2 more sources
The Journal of Cardiovascular Surgery
Endovascular arterial recanalization has become the mainstay therapy for peripheral arterial occlusive disease. Although immediate technical success is achieved in greater than 90% of cases, longer-term results continue to vary based on the clinical presentation, and the treated target lesion.
El Khoury, Rym +5 more
openaire +3 more sources
Endovascular arterial recanalization has become the mainstay therapy for peripheral arterial occlusive disease. Although immediate technical success is achieved in greater than 90% of cases, longer-term results continue to vary based on the clinical presentation, and the treated target lesion.
El Khoury, Rym +5 more
openaire +3 more sources
Costs of coronary restenosis (Lovastatin Restenosis Trial)
The American Journal of Cardiology, 1996Within the Lovastatin Restenosis Trial, restenosis has been clearly shown to increase resource utilization and costs. While it is not possible to generalize these results to other patient populations, it is clear that successful efforts to decrease restenosis will certainly improve efficacy while decreasing follow-up costs and increasing the cost ...
S P, Gilbert +3 more
openaire +2 more sources